Masahiro Kaneko

Japanese Foundation For Cancer Research

Papers

1

Total Citations

6

H-Index

1

About

Masahiro Kaneko is a leading figure in radiation oncology, with a focused expertise in ultrahypofractionated treatments for prostate cancer. His major contribution lies in systematically comparing high-dose-rate brachytherapy (HDR-BT) with robotic and conventional stereotactic body radiotherapy (SBRT), providing critical insights into treatment planning and clinical outcomes. His landmark 2023 study, which has garnered 6 citations, directly addresses the growing use of ultrahypofractionation by evaluating dosimetric differences and potential benefits of each modality. This work helps clinicians make evidence-based decisions when selecting between these advanced techniques. Kaneko’s research is highly impactful for its practical relevance, guiding the optimization of radiation delivery to improve tumor control while minimizing toxicity. His comparative analyses are essential reading for radiation oncologists and medical physicists seeking to refine prostate cancer management. Through his rigorous methodology and clear clinical focus, Kaneko continues to shape the landscape of modern radiotherapy, offering valuable benchmarks for future studies and clinical protocols.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer
6 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Japanese Foundation For Cancer Research

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago